证券代码：688617 证券简称： 惠泰医疗 公告编号：2021-046 深圳惠泰医疗器械股份有限公司 关于参加 2021 深圳辖区"沟通传递价值，交流创造良好生 态"上市公司投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流工作，深圳惠泰医疗器械股份有限公司 （以下简称"公司"）将参加由深圳上市公司协会、深圳市全景网络有限公司共 同举办的"沟通传递价值，交流创造良好生态"—2021 深圳辖区上市公司投资 者网上集体接待日活动，现将有关事项公告如下： 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台，采取网 络远程的方式举行，投资者可以登录"全景•路演天下"网站（http://rs.p5w.net/） 或关注微信公众号：全景财经，参与公司本次投资者集体接待日活动，活动时间 为 2021 年 11 月 30 日 14:00 至 17:00。 届时公司的董事、副总经理、财务负责人、董事会秘书戴振华先生将通过网 络文字交流形式与投资者进行沟通。 欢迎广大投资者 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2021, representing a year-on-year increase of 20%[1]. - The gross profit margin for the first half of 2021 was 45%, compared to 40% in the same period last year[1]. - The company's operating revenue for the first half of 2021 was CNY 384,740,292.01, representing a 99.44% increase compared to CNY 192,908,973.97 in the same period last year[16]. - Net profit attributable to shareholders was CNY 114,853,593.06, up 186.24% from CNY 40,125,326.35 year-on-year[16]. - The net cash flow from operating activities increased by 202.80%, reaching CNY 111,392,591.94, primarily due to faster cash collection from sales[16]. - The company reported a net profit of 14,228,788.27 for the first half of 2021, with a significant impact from non-operating income and expenses[21]. - The company achieved a total comprehensive income of 114,853,593.06 RMB for the first half of 2021[192]. - The total comprehensive income for the first half of the year is CNY 40,125,326.35, which contributes to the overall equity increase[194]. Research and Development - The company has allocated RMB 30 million for research and development in new technologies for the upcoming fiscal year[1]. - The company's R&D investment accounted for 13.07% of operating revenue, a decrease of 2.08 percentage points compared to the previous year, although R&D spending increased by 72.08%[17]. - The company achieved a total R&D investment of ¥50,289,683.38, representing a 72.08% increase compared to the previous period[39]. - The company has developed several core technologies, including a wire mesh reinforced extrusion technology that improves production efficiency by approximately 10 times while significantly reducing costs[34]. - The company is developing innovative products aimed at improving cardiac electrophysiology procedures, with several projects in the clinical trial phase[43]. - The company has established R&D centers in Shenzhen, Hunan, and Shanghai, focusing on electrophysiological consumables and vascular intervention devices[52]. Market Expansion and Product Development - The company plans to launch two new medical devices by the end of 2021, aiming to capture an additional 10% market share in the cardiovascular segment[1]. - The company is focused on expanding its product offerings in high-value medical consumables and interventional devices[22]. - The company plans to continue market expansion and enhance channel management to optimize product performance across all product lines[19]. - The company is positioned to benefit from the increasing healthcare spending and awareness among the population, driving further growth in the medical device market[22]. - The company launched its peripheral vascular intervention products in 2019, focusing on tumor embolization and peripheral vascular treatment, with a unique domestic adjustable valve catheter sheath approved for market[28]. Corporate Governance and Compliance - The company is committed to improving its corporate governance and has implemented new policies to enhance transparency and accountability[1]. - The company has established internal control systems for waste gas and waste water treatment, ensuring compliance with relevant laws and standards[95]. - The company has maintained strict adherence to its commitments, with all promises fulfilled within the specified timeframes[100]. - The company has ensured compliance with relevant laws and regulations regarding related party transactions and corporate governance[138]. Risks and Challenges - The company has identified key risks including regulatory changes and supply chain disruptions, with strategies in place to mitigate these risks[1]. - The company faces risks related to new product development failures and registration challenges, which could impact revenue and profitability[66]. - The company is exposed to market competition risks, with foreign brands holding over 80% of the domestic market share in the electrophysiology and vascular intervention sectors[68]. Shareholder Commitments and Stock Management - The controlling shareholder and actual controller have committed to not transferring or managing their shares for 36 months post-listing[103]. - The company will ensure compliance with relevant laws and regulations in all share transactions and commitments made by shareholders[112]. - The company will publicly disclose reasons for any failure to fulfill commitments and apologize to shareholders and investors[131]. - The controlling shareholders have pledged to support the company's long-term development and will not sell shares during the lock-up period[110]. Financial Position and Assets - Total assets grew by 216.25% to CNY 1,861,792,003.56, while net assets attributable to shareholders increased by 260.22% to CNY 1,658,312,682.12, mainly due to funds raised from the IPO[16]. - The company's total liabilities increased to CNY 215,337,583.60 from CNY 138,624,793.36, indicating a growth of approximately 55.5%[178]. - The company's equity attributable to shareholders reached CNY 1,658,312,682.12, a substantial increase from CNY 460,356,245.64, marking a growth of around 260%[178]. - The company reported a significant increase in prepayments, which rose by 236.55% to 31,155,789.95 RMB, due to expanded sales scale[78]. Environmental Responsibility - The company has not faced any administrative penalties related to environmental issues during the reporting period[95]. - The company has committed to long-term promises regarding share restrictions and compliance with regulations, ensuring stability in shareholder structure[99]. - The company has engaged qualified units for the disposal of hazardous waste, ensuring compliance with environmental regulations[97].